Understanding Nsclc Treatment When You Have An...
9.8 K
5:03
Osimertinib In Advanced Nonsmall-Cell Lung Cancer
45.7 K
2:21
Overcoming Egfr-Tki Resistance Emerging Therapies...
46
30:06
Egfr And Lung Cancer
3.4 K
1:20
Mechanisms Of Resistance To Egfr Tki And New...
5.3 K
21:09
Egfr Tki Resistance Targeting Met Amplification
686
8:00
The Egf Receptor Tyrosine Protein Kinases
35.7 K
3:47
Harmoni-A Ivonescimab Chemo After Egfr-Tki...
40
6:35
Ramalingam Compares Third Generation Egfr Tki...
369
0:53
2-Step Dose-Escalation To Establish Resistance In...
33
2:01
Egfr-Tki Therapy In Advanced Nsclc
358
3:12
Exploring Neoadjuvant Egfr-Tkis In Lung Cancer
122
1:18
Egfr Tki With Chemotherapy In Nsclc Os Vs Pfs
3
20:03
Egfr Tki Sequencing
192
5:45
Two Mechanisms Of Acquired Resistance To Egfr Tkis
1.8 K
1:05
Egfr Tki Side Effects A Clinician S Guide
1
7:50
Should Egfr Tki Therapy Be Continued Beyond...
150
그리는 과학 70화 암 돌연변이 너만 보인단 말이야 표적 치료제 Egfr Tyrosine...
1.5 K
3:03
Dr. Sequist On Frontline Egfr Tki Use In Nsclc
235
Tki-Resistant Egfr-Mutant Nsclc
3 K
20:35
Managing Patients With Egfr Exon 20 Ins In Nsclc...
792
16:16
Nsclc With Egfr Exon 20 Shows Benefit With...
429
2:03
Dacomitinib Dark Horse Egfr Tki Charges Into...
584
7:54
Third Generation Egfr Tkis For Acquired Resistance
190
3:07
2021 West Oncology Lung Cancer Egfr Mutation...
2.2 K
20:34
Dr. Mark Kris Discusses Dacomitinib For Patient...
528
1:36
Debate Drug Of Choice For Exon 19 Del Egfr Mutant...
1.6 K
13:26
Jack West, Md Use Of Tki Therapy In Patients With...
461
1:48
Dr. Heather Wakelee On What To Do When Resistance...
414
The Flaura Trial Practice-Changing Results For...
9:36
Dr. Ramalingam On The Role Of Osimertinib In Egfr...
837
1:40
Osimertinib Plus Gefitinib For Treatment Of...
2.3 K
3:31
Rociletinibosimertinib For Egfr T790M-Negative...
953
5:20
Managing T790-Negative Egfr-Mutated Nsclc
373
13:06
イレッサ最初のEgfr-Tki
8:28
Treating Nonsmall Cell Lung Cancer With An Egfr...
2.1 K
4:47
Vila - Afatinib Egfr Tki Thế Hệ 2 Trong Điều Trị...
687
27:36
Long Term Management Of Egfr-Mutant Nsclc -Tsao
1.7 K
21:35
Prolonging Survival In Nsclc
4 K
2:18
3Rd Generation Drug For Acquired Resistance In...
488
4:10